New approach identifies reproducible volatile organic compounds for lung cancer diagnosis
A research team has developed a multi-medium approach (MMA) to identify reproducible volatile organic compounds (VOCs) in ...
The Harvard Crimson1d
HMS Research Identifies Metabolic Enzyme that Facilitates Lung Cancer Growth
Researchers at the Harvard Medical School discovered that the enzyme GUK1 promotes lung cancer growth by boosting the ...
GlobalData on MSN2d
Health Canada approves MSD’s Keytruda for NSCLC stages
Health Canada has approved MSD's anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating adults with ...
Targeted Oncology4d
AI Prognostic Tool for NSCLC Earns FDA Breakthrough Designation
The FDA granted breakthrough status to Serial CTRS, an AI tool that improves survival predictions in non–small cell lung ...
Cure Today4d
THIO and Libtayo Extends OS in NSCLC Following Progression on SOC Therapy
THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...
BioWorld7d
Henlius lands European approval of PD-1 lung cancer drug
The European Commission on Feb. 5 cleared Shanghai Henlius Biotech Inc.’s serplulimab (HLX-02) under the brand name of Hetronifly as a first-line combination therapy with carboplatin and etoposide to ...
中国日报网8d
Shanghai Henlius Biotech's lung cancer drug gets EU approval
Hong Kong-listed Shanghai Henlius Biotech Inc, a subsidiary of Fosun Pharma, announced on Wednesday that its anti-PD-1 mAb, ...
Immuneering and Regeneron partner on lung cancer trial
CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...
earth10d
Computer model can identify tumor-fighting immune cells
Researchers have developed a groundbreaking AI model that identifies tumor-fighting immune cells, enhancing cancer ...
Science Daily10d
Computer model helps identify cancer-fighting immune cells key to immunotherapy
Researchers have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors.